MD Anderson Cancer Center
Ibrutinib keeps CLL in check

Targeted therapy thwarts chronic lymphocytic leukemia 2 years into clinical trial. Susan O’Brien, M.D., of Leukemia explains impact of ibrutinib.
Video is loading...
Title: Ibrutinib keeps CLL in check
Summary: Targeted therapy thwarts chronic lymphocytic leukemia 2 years into clinical trial. Susan O’Brien, M.D., of Leukemia explains impact of ibrutinib.
Keywords: MD Anderson,cancer center,cancer,cancer treatment,chronic lymphocytic leukemia,ibrutinib,cll,ash, integratedComm, Communications - Integrated Media
Transcript: